Quest Diagnostics (NYSE:DGX) Earns Buy Rating from Analysts at Redburn Atlantic
Redburn Atlantic began coverage on shares of Quest Diagnostics (NYSE:DGX – Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $195.00 price objective on the medical research company’s stock. DGX has been the subject of a number of other reports. Leerink Partners raised Quest Diagnostics […]
Redburn Atlantic began coverage on shares of Quest Diagnostics (NYSE:DGX – Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a buy rating and a $195.00 price objective on the medical research company’s stock. DGX has been the subject of a number of other reports. Leerink Partners raised Quest Diagnostics […]
